Sugi Predict

Sugi Predict / Compounds / SCHEMBL2954535

SCHEMBL2954535

SCHEMBL2954535

CCCCCCN(CCCCCC)C(=N)NC(=N)N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA2 P00918 1/20 0.42
▸ SPHK1 Q9NYA1 4/20 0.42
▸ SPHK2 Q9NRA0 1/20 0.42
▸ MGLL Q99685 1/20 0.39
▸ DNM1 Q05193 3/20 0.37
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ GRIN2D O15399 1/20 0.35
▸ GRIN3B O60391 1/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ GRIN2A Q12879 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ GRIN2C Q14957 1/20 0.35
▸ GRIN3A Q8TCU5 1/20 0.35
▸ ZDHHC20 Q5W0Z9 1/20 0.33
▸ ZDHHC2 Q9UIJ5 1/20 0.33
▸ GBA1 P04062 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8498288 1.00 CA12 (0.42) CA12CA1CA9CA2SPHK1
SCHEMBL8495268 1.00 CA12 (0.42) CA12CA1CA9CA2SPHK1
SCHEMBL28905825 1.00 CA12 (0.42) CA12CA1CA9CA2SPHK1
SCHEMBL8499444 1.00 CA12 (0.42) CA12CA1CA9CA2SPHK1
SCHEMBL28415126 0.98 CA12 (0.41) CA12CA1CA9CA2SPHK1
Hydrochloric Acid SCHEMBL4483541 0.98 CA12 (0.41) CA12CA1CA9CA2SPHK1
Hydrochloric Acid SCHEMBL19371460 0.98 CA12 (0.41) CA12CA1CA9CA2SPHK1
SCHEMBL28417961 0.98 CA12 (0.41) CA12CA1CA9CA2SPHK1
Hydrochloric Acid SCHEMBL4484498 0.98 CA12 (0.41) CA12CA1CA9CA2SPHK1
SCHEMBL2955338 0.98 CA12 (0.39) CA12CA1CA9CA2SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. 2020-09-03 — — US claimed
US-10626085-B2 Biguanide compound and use thereof IMMUNOMET THERAPEUTICS INC. (US) 2020-04-21 — — US claimed
US-20180044283-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2018-02-15 — — US claimed
EP-3222614-A2 BIGUANIDE COMPOUND AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-09-27 — — EP claimed
CN-107108536-A Biguanide compound and application thereof 伊谬诺米特医疗有限公司 2017-08-29 — — CN claimed
CN-102725264-A Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient HANALL BIOPHARMA CO LTD 2012-10-10 — — CN claimed
EP-1753861-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN Dynamis Therapeutics, Inc. (US) 2007-02-21 — — EP claimed
WO-2005079463-A2 FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN DYNAMIS THERAPEUTICS, INC. (US) 2005-09-01 — — WO claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 — — US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 — — US claimed
US-11572341-B2 Biguanide compound and use thereof IMMUNOMET THERAPEUTICS INC. (US) 2023-02-07 — — US disclosed
US-11572341-B2 Biguanide compound and use thereof IMMUNOMET THERAPEUTICS INC. (US) 2023-02-07 — — US disclosed
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. 2020-09-03 — — US disclosed
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC. 2020-09-03 — — US disclosed
EP-3222614-B1 BIGUANIDE COMPOUND AND USE THEREOF IMMUNOMET THERAPEUTICS INC (US) 2020-07-29 — — EP disclosed
EP-1175155-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2002-01-30 — — EP disclosed
WO-2000062626-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2000-10-26 — — WO disclosed
US-5254593-A Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking THE ROCKEFELLER UNIVERSITY (US) 1993-10-19 — — US disclosed
WO-1992007560-A1 BIGUANIDES AND DERIVATIVES THEREOF AS INHIBITORS OF ADVANCED GLYCOSYLATION OF A TARGET PROTEIN THE ROCKEFELLER UNIVERSITY (US) 1992-05-14 — — WO disclosed
US-5100919-A Aging resistance; food preservatives THE ROCKEFELLER UNIVERSITY (US) 1992-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626085-B2 Biguanide compound and use thereof MKI67, GCG, GCKR CA12 2765/4885CA1 2719/4885CA9 783/4885
US-20180044283-A1 BIGUANIDE COMPOUND AND USE THEREOF MKI67, GCG, GCKR CA12 2765/4885CA1 2719/4885CA9 783/4885
US-11572341-B2 Biguanide compound and use thereof MKI67, GCG, GCKR CA12 2765/4885CA1 2719/4885CA9 783/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 CA12 2292/4885CA1 4084/4885CA9 1973/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE CA12 4810/4885CA1 4767/4885CA9 3366/4885
US-20200277255-A1 BIGUANIDE COMPOUND AND USE THEREOF MKI67, GCG, GCKR CA12 2765/4885CA1 2719/4885CA9 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.